ArticleJournal of asthma and allergy2026
Associations Between Social Determinants of Health and Adherence to Biologic Therapies in Patients with Severe Asthma: Real-World Evidence from a Large US Claims Analysis.
Article in Journal of asthma and allergy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Real-World Comparative Effectiveness of Mepolizumab versus Benralizumab in an Older Population with Asthma: A US Medicare Fee-for-Service Analysis.Journal of asthma and allergy · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: This study describes factors associated with biologic initiation and adherence, and impacts of adherence on exacerbations among US patients with severe asthma. Patients and Methods: This retrospective cohort study defined two populations, biologic-eligible patients and biologic users, using the Komodo Research Database of healthcare claims (2016-2024). The biologic-eligible cohort was defined as patients with severe asthma who had ≥2 exacerbations within 12 months, after the severe asthma index date. Severe asthma was defined as ≥3 month medium-to-high-dose inhaled corticosteroid use with ≥1 overlapping supply with controller therapy. The severe asthma index date was the first day of overlapping treatment supply. Biologic users were defined as patients with ≥2 dispensings of the same biologic and ≥2 asthma diagnoses in the year prior to biologic initiation. In the biologic-eligible cohort, biologic initiation was evaluated and compared between less- and more-favored social determinants of health (SDOH) areas (based on census-level quartiles). Adherence (assessed based on refills and treatment gaps) and exacerbations were assessed among biologic users in the 12 months following biologic initiation and compared between less- and more-favored SDOH areas. Results: Overall 29,652 patients had ≥2 years of follow-up in the biologic-eligible cohort. Of these, 11.3% (n=3362) initiated biologics. In total, 16,336 patients were included in the biologic-user cohort, among whom 62.6% were adherent, 12.1% partially adherent, 3.1% minimally adherent, and 22.3% discontinued treatment. Biologic initiation and adherence were lower in less- versus more-favored SDOH areas. Compared with adherent patients, those who were partially/minimally adherent or discontinued treatment in the 12 months following biologic initiation had significantly more exacerbations post-landmark period (+18% overall and +28% hospitalization-defined exacerbations). Conclusion: Disparities in biologic initiation and adherence exist between severe asthma populations with different characteristics and SDOH. Biologic adherence is associated with fewer exacerbations compared with partial adherence, minimal adherence, and treatment discontinuation.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.